Faricimab (Vabysmo, Roche, EU) may improve treatment durability while maintaining functional and anatomical outcomes in neovascular age-related macular degeneration (nAMD). This single-centre retrospective study evaluated 52 eyes of 49 refractory nAMD patients switched from ranibizumab, aflibercept 2 mg, or brolucizumab to faricimab. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), injection intervals, optical coherent tomography (OCT) fluid, and adverse events were assessed at baseline and last follow-up. Mean age was 78.8 years. Before switching, patients had received a mean of 21.85 injections over 996 days, and 77.4% were short responders, with a mean treatment interval of 6.3 weeks. After a mean 466 days of faricimab treatment, BCVA remained stable, changing from 0.389 to 0.378 logMAR (mean change −0.012 logMAR; p = 0.509). BCVA improved in 19.2%, remained stable in 67.3%, and worsened in 13.5% of eyes. CRT decreased significantly from 257.8 to 224.8 μm (mean change −32.9 μm; p = 0.00005). The mean injection interval increased to 8.0 weeks, reaching 8.42 weeks among eyes continuing faricimab. Thirteen eyes (25%) required switching to aflibercept 8 mg because of recurrent fluid or OCT worsening. No endophthalmitis or severe intraocular inflammation occurred. Faricimab maintained vision, improved macular anatomy, and reduced treatment burden, although some refractory eyes required further treatment escalation.